Lilly nabs EU approval for Trulicity; Sinclair Pharma may sell itself; Genentech defends cancer drug shift;

@FiercePharma: U.K. gatekeepers toughest on cancer meds--and getting tougher all the time. More | Follow @FiercePharma

@CarlyHFierce: Lundbeck CEO exits in disgrace, endangering key new launches. Story | Follow @CarlyHFierce

> Eli Lilly ($LLY) won the final nod from European regulators for its diabetes treatment Trulicity, a challenger for Novo Nordisk's ($NVO) Victoza; it's planning a rollout in 2015. Release | Report

> Sinclair IS Pharma says it's considering options for the company, including selling all or part of itself, or perhaps arranging licensing and co-marketing deals. Report

> Roche's ($RHHBY) Genentech unit once again defended its decision to narrow distribution on its three best-selling cancer drugs after purchasing agent Novation placed an open letter in The New York Times. Report

> U.S. lawmakers are looking for ways to combat recent price hikes for generic drugs, including legislation that would allow imports from Canada. Report

Medical Device News

@FierceMedDev: Reva raises $25M to get CE mark for bioresorbable scaffold. Article | Follow @FierceMedDev

@VarunSaxena2: Updated with more information from Bloomberg: Stryker said to be interested in buying Smith & Nephew (once again). More | Follow @VarunSaxena2

@EmilyWFierce: $BSX sinks some funds into an Iowa-based startup developing an ablation device for atrial fibrillation. Story | Follow @EmilyWFierce

> Researchers develop 'Wi-Fi'-triggered dissolvable, implantable device for drug delivery. Story

> Covidien gets 510(k) for peripheral balloon catheter aimed at hemodialysis patients. More

Biotech News

@FierceBiotech: Cell Medica hauls in $78M to get its #cancer immunotherapy through Phase II. Story | Follow @FierceBiotech

@JohnCFierce: Trending - UPDATED: J&J jumps into hot CAR-T field with gene-editing experts at Transposagen. Article | Follow @JohnCFierce

@DamianFierce: $BMRN + $RNA sub-question: Does drisapersen qualify for a future rare pediatric disease voucher? | Follow @DamianFierce

> Cell Medica hauls in $78M to get its cancer immunotherapy through Phase II. Story

> Novartis' troubled blood cancer drug is now less of an FDA priority. More

> Report: Woodford is diving full on into biotech with new $314M fund. Article

Biotech Research News

> Autoimmune experts discover a new pathway for multiple sclerosis R&D. Story

> U.K.'s MRC outlicenses Parkinson's discovery program to China's Yabao. More

> Nanotech team mounts a search-and-destroy mission against cancer cells. Article

> UC Irvine investigators spotlight a new class of 'chemosensitizers.' News

> Rodent studies point to a new target for ovarian cancer R&D. Story

Pharma Manufacturing News

> Merck KGaA to power India plant with coconut and cashew shells. More

> AbbVie buys API plant in Singapore where it's already building one. News

> Baxter labeling issue could leave patients short on potassium chloride. Story

> Merck manufacturing know-how brought to bear on NewLink Ebola vaccine. Item

> AstraZeneca joins Bristol-Myers, Amgen in biologics buildup. Article

And Finally... Salix Pharmaceuticals ($SLXP) says it's on the hunt for new directors for an expanded board. Release

Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.